Sofinnova Partners Research
Investment Thesis
Sofinnova Partners is a Paris-headquartered life sciences venture capital firm founded in 1972, making it one of the oldest continuously operating VC firms in Europe. The firm's guiding principle, "Partners for Life," reflects a philosophy of building long-term, trust-based relationships with entrepreneurs rather than transactional deal-making. Sofinnova Partners backs founders and scientists working on breakthrough innovations in biopharma, medtech, digital medicine, agriculture, and industrial biotechnology, with the stated belief that treating patients well and solving hard scientific problems ultimately produces strong financial returns. Over more than 50 years, the firm has backed more than 500 companies and today manages over €4 billion in assets. It positions itself as a "company creator," frequently founding or co-founding businesses around scientific breakthroughs rather than only investing in already-formed teams.
Sector Focus
The firm operates across the full life sciences value chain through seven distinct, specialist-led investment strategies:
- Sofinnova Capital — the flagship fund; founding or lead investor in early-stage biopharma and medtech start-ups developing novel therapeutic technologies.
- Sofinnova MD Start — an in-house medtech accelerator that creates and launches early-stage medtech companies through hands-on company building.
- Sofinnova Crossover — invests in growth-stage biotech and medtech companies that have clinically validated their technology and are preparing for commercialization.
- Sofinnova Industrial Biotech — early-stage sustainable companies across agriculture, chemicals, food, and materials.
- Sofinnova Telethon — early-stage investments in leading Italian life science research, in partnership with the Telethon Foundation.
- Sofinnova Digital Medicine — early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation (including AI-driven biology platforms).
- Sofinnova Biovelocita — a biotech accelerator partnering with leading research organizations to create and build European biotech start-ups.
Stage Focus
Sofinnova Partners invests across the full life sciences company lifecycle: company creation and pre-seed (MD Start, Biovelocita), seed and Series A (Capital, Telethon), and growth-stage/clinically-validated companies preparing for commercialization (Crossover). The firm frequently acts as founding or first institutional investor for companies it helps create in-house.
Check Size
Exact check-size ranges are not disclosed on the firm's website. Public secondary sources reference deployments in the tens of millions of dollars per round for later-stage Crossover deals, consistent with a firm managing €4B+ across seven strategies, but this figure is not independently confirmed by Sofinnova Partners directly and is treated here as low-confidence.
Lead Tendency
The Capital Strategy explicitly states it invests "as founding or lead investor," and the firm's own description of itself as a "company creator" (via MD Start and Biovelocita) further indicates a strong lead/founding orientation rather than a pure follower posture.
Recent Activity
Sofinnova Capital XI, the firm's latest flagship fund, closed in November 2025 at €650 million (~$750M), exceeding its original target — its largest fund to date and a signal of continued active deployment. Recent portfolio news (September 2026) includes a $90M+ raise by HighLife to fund a US pivotal study, a SEK 75M round for EnginZyme, leadership appointments at ProQR and Julier Medical, half-year results from Sensorion, a Phase 1 dosing milestone at Bionyra, and NodThera's rebrand to Rezera alongside a Phase 3 program announcement.
Portfolio Highlights
The portfolio spans more than 140 current and historical companies across biopharma, medtech, digital medicine, and industrial biotech. Notable names include Shockwave Medical, ReCor Medical, RefleXion Medical, Ascendis Pharma, Innate Pharma, DBV Technologies, GenSight Biologics, Verona Pharma, MaxCyte, Abivax, Sensorion, Inventiva, Hookipa Pharma, and AI-native biology platforms such as Bioptimus and Latent Labs.
Team
Sofinnova Partners is led by a trio of Managing Partners — Antoine Papiernik (Chairman & Managing Partner), Graziano Seghezzi, and Henrijette Richter — with each of the seven strategies run by its own dedicated partner-led team (e.g., Maina Bhaman, Anta Gkelou, and Karl Naegler on Capital; Jacques Theurillat, Joe Anderson, and Cedric Moreau on Crossover; Guillaume Baxter and Michael Krel on Industrial Biotech; Cécile Dupont, Mano Iyer, and Anne Osdoit on MD Start; Lucia Faccio and Paola Pozzi on Telethon; Edward Kliphuis and Simon Turner on Digital Medicine; and Gabriella Camboni, Matthieu Coutet, Alex Leech, and Zhizhong Joel Yao on Biovelocita). The firm also maintains a substantial corporate services bench (legal, finance, investor relations, HR, communications) reflecting its scale and multi-strategy structure.
Decision Process
With three Managing Partners at the top and dedicated partner teams for each of seven strategies, Sofinnova Partners operates as a multi-strategy partnership rather than a solo-GP or single investment-committee structure.
Founder Preferences
The firm's public materials and partner quotes emphasize backing founders and scientists with resilience and grit ("the ability to move mountains and stay resilient when things are not easy"), technical/scientific depth, and a genuine commitment to bringing products to patients — consistent with its company-creation model where Sofinnova often assembles the founding team itself around a scientific insight.
Geographic Focus
Sofinnova Partners is headquartered in Paris with a strong pan-European footprint (dedicated Italian focus via Telethon and Biovelocita) and meaningful US exposure — a significant share of the Capital and Crossover portfolios are US-incorporated companies (e.g., Shockwave Medical, ReCor Medical, RefleXion Medical, HotSpot Therapeutics, Mozart Therapeutics, Nitrase Therapeutics).